SEC Form 4 · accession 0001193125-26-354018
Sagimet Biosciences Inc. · SGMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Kemble
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 17, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001400118
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common Stock | Aug 14, 2026 | M | 326,618 | $6.36 | A | 388,779 | D | |
| Series A Common Stock | Aug 14, 2026 | M | 24,369 | $6.36 | A | 413,148 | D | |
| Series A Common StockF2 | Aug 14, 2026 | S | 350,987 | $10.2328 | D | 62,161 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $6.36 | Aug 14, 2026 | M | 326,618 | D | — | Apr 27, 2029 | Series A Common Stock | 326,618 | 31,455 | D |
| Stock Option (Right to Buy)F3 | $6.36 | Aug 14, 2026 | M | 24,369 | D | — | Apr 27, 2029 | Series A Common Stock | 24,369 | 11,608 | D |
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3This option is fully vested and exercisable as of the date hereof.